Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris

Hadassah Medical Center

Status and phase

Completed

Phase 2

Phase 1

Conditions

Acne Vulgaris

Treatments

Drug: salicylic acid

Drug: clindamycin phosphate

Study type

Interventional

Funder types

Other

Identifiers

NCT00361322

CLSA-HMO-CTIL

Details and patient eligibility

About

The concept behind our study was to combine an effect of antibiotic and anti-inflammatory agents for a more efficient acne therapy directed at the factors involved in the pathophysiology of the disease. For this purpose we evaluated a combination of clindamycin phosphate and salicylic acid in a non-irritating carrier.

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

mild to moderate acne vulgaris;
at least 5 lesions on the face;
a one-month wash-out period was established for any topical or systemic drug use for treatment of acne vulgaris.

Exclusion criteria

acne that was primarily truncal, nodular, or due to secondary causes/internal disease;
pregnancy, breastfeeding, or intention to become pregnant;
another dermatological disease of the face;
significant systemic disease;
any drug/alcohol addiction;
interacting medication;
known hypersensitivity to study medications;
history of chronic disease treated with medications which might affect acne condition and treatment outcome (e.g. corticosteroids, lithium, isoniazid, anti-androgens, phenytoin, phenobarbital) in the preceding month